Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Open-Label Study of Sacituzumab Govitecan in Japanese Patients With Advanced Solid Tumors (ASCENT-J02)

NCT05101096 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT05101096
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05101096 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Open-Label Study of Sacituzumab Govitecan in Japanese Patients With Advanced Solid Tumors (ASCENT-J02)
Lead sponsor
Gilead Sciences
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
October 20, 2021
Completion date
May 31, 2027
Enrollment
135 (actual)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, hr+/her2- metastatic breast cancer, metastatic triple-negative breast cancer, metastatic urothelial cancer